COSTEM 2022 | Can adding ATG to PTCy further reduce the risk of GvHD?
Alexandros Spyridonidis
• 29 Oct 2022
Alexandros Spyridonidis, MD, University of Patras, Patras, Greece, comments on combining anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) in graft-versus-host disease (GvHD) prophylaxis. Whilst both in isolation are used to prevent GvHD, simultaneously administering both has not been assessed. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
